- Home
- BRBS vs ITOS Comparison
BRBS vs ITOS Comparison
Compare BRBS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRBS
- ITOS
- Stock Information
- Founded
- BRBS 1893
- ITOS 2011
- Country
- BRBS United States
- ITOS United States
- Employees
- BRBS N/A
- ITOS N/A
- Industry
- BRBS Commercial Banks
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRBS Finance
- ITOS Health Care
- Exchange
- BRBS Nasdaq
- ITOS Nasdaq
- Market Cap
- BRBS 284.6M
- ITOS 280.6M
- IPO Year
- BRBS N/A
- ITOS 2020
- Fundamental
- Price
- BRBS $3.35
- ITOS $8.00
- Analyst Decision
- BRBS
- ITOS Strong Buy
- Analyst Count
- BRBS 0
- ITOS 3
- Target Price
- BRBS N/A
- ITOS $21.33
- AVG Volume (30 Days)
- BRBS 224.4K
- ITOS 470.7K
- Earning Date
- BRBS 01-29-2025
- ITOS 03-05-2025
- Dividend Yield
- BRBS N/A
- ITOS N/A
- EPS Growth
- BRBS N/A
- ITOS N/A
- EPS
- BRBS N/A
- ITOS N/A
- Revenue
- BRBS $97,608,000.00
- ITOS $35,000,000.00
- Revenue This Year
- BRBS N/A
- ITOS $271.18
- Revenue Next Year
- BRBS N/A
- ITOS N/A
- P/E Ratio
- BRBS N/A
- ITOS N/A
- Revenue Growth
- BRBS N/A
- ITOS N/A
- 52 Week Low
- BRBS $2.33
- ITOS $7.09
- 52 Week High
- BRBS $3.69
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- BRBS 55.23
- ITOS 53.50
- Support Level
- BRBS $3.21
- ITOS $7.63
- Resistance Level
- BRBS $3.43
- ITOS $8.09
- Average True Range (ATR)
- BRBS 0.09
- ITOS 0.30
- MACD
- BRBS 0.01
- ITOS 0.06
- Stochastic Oscillator
- BRBS 60.61
- ITOS 74.11
About BRBS Blue Ridge Bankshares Inc.
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, credit cards, online banking, telephone banking, mobile banking, and other activities to other businesses, professionals, consumers, nonprofits, and municipalities. Its primary source of revenue is interest income from the lending activities.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.